Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis

被引:2
作者
Lee, Ji Yae [1 ]
Kim, Sue [2 ]
Lee, Yaeji [3 ]
Kwon, Yu-Jin [4 ]
Lee, Ji-Won [1 ,5 ]
机构
[1] Yonsei Univ, Severance Hosp, Coll Med, Dept Family Med, Seoul 03722, South Korea
[2] Yonsei Univ Hlth Syst, Severance Hosp, Int Hlth Care Ctr, Seoul 03722, South Korea
[3] Yonsei Univ, Dept Biostat & Comp, Seoul 03722, South Korea
[4] Yonsei Univ, Yongin Severance Hosp, Coll Med, Dept Family Med, Yongin 16995, South Korea
[5] Yonsei Univ, Severance Hosp, Dept Family Med, Coll Med,Inst Innovat Digital Healthcare, Yonsei Ro 50-1, Seoul 03722, South Korea
基金
新加坡国家研究基金会;
关键词
Mediterranean diet adherence; steatotic liver disease; metabolic dysfunction-associated steatotic liver disease; alcohol-related liver disease; CARDIOVASCULAR-DISEASE; HEPATIC STEATOSIS; GUIDELINE; BENEFITS; NOMENCLATURE; NUTRITION; HEALTH;
D O I
10.3390/nu16203551
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and Aims: Metabolic liver disease is associated with obesity, insulin resistance, cardiovascular disease, and metabolic disorders. A Mediterranean diet (MD), known for its anti-inflammatory and antioxidant properties, is effective in managing various chronic diseases, including liver diseases. This study aimed to explore the influence of adherence to the MD on the risk of chronic metabolic diseases, including steatotic liver disease (SLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-related liver diseases (ALDs). Methods: This retrospective cohort study analyzed 5395 individuals from a single center between 2020 and 2022, grouped by adherence to the MD using the Korean Mediterranean Diet Adherence Score (K-MEDAS). MASLD score, ALD, and cardiovascular risk factors were also assessed. Statistical analyses were performed using 1:1 exact matching and multiple regression to compare the less adherent (K-MEDAS 0-7) and highly adherent (K-MEDAS 8-13) groups. Results: Adjusting for confounding variables, high adherence to the MD was significantly associated with lower rates of SLD (odds ratio [OR] 0.818, 95% confidence interval [CI] 0.700-0.957, p = 0.012), MASLD (OR 0.839, 95% CI 0.714-0.986, p = 0.033), and ALD (OR 0.677, 95% CI 0.671-0.683, p < 0.001). Post-propensity score matching analysis revealed that the highly adherent group exhibited significantly lower triglyceride levels, triglyceride and glucose index, atherogenic Index of Plasma, and Framingham risk scores than the less adherent group. Conclusions: Good adherence to the MD considerably reduces the risk of SLD, MASLD, and ALD, underscoring its protective effects and potential to prevent metabolic liver diseases and their complications.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis
    Jamil, Asma
    Chivese, Tawanda
    Elshaikh, Usra
    Sendall, Marguerite
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [22] Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults
    Chung, Goh Eun
    Yu, Su Jong
    Yoo, Jeong-Ju
    Cho, Yuri
    Lee, Kyu-na
    Shin, Dong Wook
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Han, Kyungdo
    Cho, Eun Ju
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [23] Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Oh, Juyeon
    Kim, Beom Kyung
    Yoon, Jin-Ha
    Lee, Hyung Ho
    Park, Heejoo
    Lee, Jian
    Park, Youngsun
    Yun, Byungyoon
    Chung, Jinsoo
    CANCERS, 2024, 16 (18)
  • [24] Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study
    Simon, Tracey G.
    Ebrahimi, Fahim
    Roelstraete, Bjorn
    Hagstrom, Hannes
    Sundstrom, Johan
    Ludvigsson, Jonas F.
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [25] Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
    Raggi, Paolo
    Milic, Jovana
    Manicardi, Marcella
    Cinque, Felice
    Swain, Mark G.
    Sebastiani, Giada
    Guaraldi, Giovanni
    ATHEROSCLEROSIS, 2024, 392
  • [26] Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease
    Henin, Guillaume
    Loumaye, Audrey
    Leclercq, Isabelle A.
    Lanthier, Nicolas
    JHEP REPORTS, 2024, 6 (02)
  • [27] Non-invasive testing in metabolic dysfunction-associated steatotic liver disease
    Dawod, Sanad
    Brown, Kimberly
    FRONTIERS IN MEDICINE, 2024, 11
  • [28] Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function
    Villarroel, Carolina
    Karim, Gres
    Sehmbhi, Mantej
    Debroff, Jake
    Weisberg, Ilan
    Dinani, Amreen
    GASTRO HEP ADVANCES, 2024, 3 (01): : 122 - 127
  • [29] Food insecurity is a risk factor for metabolic dysfunction-associated steatotic liver disease in Latinx children
    Maxwell, Sarah L.
    Price, Jennifer C.
    Perito, Emily R.
    Rosenthal, Philip
    Wojcicki, Janet M.
    PEDIATRIC OBESITY, 2024, 19 (06):
  • [30] Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
    Gambardella, Maria Luisa
    Abenavoli, Ludovico
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)